Transitions 2005
Transitions is a video that explores some of the issues and challenges “dual eligibles” may face during the transition from Medicaid drug coverage to Medicare.
View the Latest: Medicare Part D
Filter
-
-
Analysis of Medicare Prescription Drug Plans In 2012 And Key Trends Since 2006
ReportThis report presents findings from an analysis of the Medicare Part D marketplace in 2012 and changes in drug coverage and costs since 2006.
-
Report, Briefing Examine How Seniors Choose Among Their Medicare Plan Options
News ReleaseReport & Briefing Examine How Seniors Choose Among Their Medicare Plan Options Seniors appreciate having a wide range of Medicare private plan choices available to them but often feel unqualified to choose among them, a new Kaiser Family Foundation report concludes.
-
The Medicare Part D Coverage Gap: Costs and Consequences in 2007
ReportThis study quantifies the number of Medicare Part D plan enrollees in 2007 who reached a gap in their prescription drug coverage known as the “doughnut hole,” as well as the changes in beneficiaries’ use of medications and out-of-pocket spending after they reached that gap.
-
What’s Next for Medicare Negotiated Drug Prices Under the Trump Administration?
Quick TakeThe Trump Administration could go in one of three directions with the Medicare negotiations program: stay the course, water it down or repeal it all together. There are potential tradeoffs with each, but the first would be most popular.
-
Workforce Reductions at Social Security Could Affect Medicare and Medicaid Coverage
Quick TakeHow these new workforce reductions at the Social Security Administration will affect people is unknown but could make it harder for people to get connected to benefits they might qualify for…which would in turn affect access to health insurance coverage through Medicare and Medicaid.
-
KFF Health Tracking Poll July 2023: The Public’s Views Of New Prescription Weight Loss Drugs And Prescription Drug Costs
FeatureAbout half of adults are interested in taking prescription weight loss drugs. though interest drops when presented with obstacles or drawbacks. Many adults struggle with affording prescription drugs and say there should be more price regulation. Few are aware of provisions in the 2023 Inflation Reduction Act aimed at lowering the drug price for Medicare beneficiaries
-
Probing the Legal Arguments in the Drug Industry’s Challenges to Medicare Drug Price Negotiations
Event Date:EventWith the Biden administration’s announcement of the first 10 drugs to be negotiated for Medicare as part of the Inflation Reduction Act (IRA), an array of legal challenges from the pharmaceutical industry is potentially the biggest obstacle to implementation. On Tuesday, September 12, two legal experts and a health policy expert joined Larry Levitt, executive vice president for health policy at KFF, for a 45-minute discussion about the legal issues underpinning these lawsuits and how they intersect with the policy goals of the legislation.
-
A Current Snapshot of the Medicare Part D Prescription Drug Benefit
Issue BriefThis brief provides an overview of the Medicare Part D prescription drug benefit, including current data on plan availability, enrollment, and spending and financing, and highlights changes made under the Inflation Reduction Act.
-
Medicare Advantage Payments to Increase Again
Quick TakeThe increase translates into an additional $35 billion to Medicare Advantage plans in 2026 compared to this year….The increase in payments is larger than for 2025 (3.7%) or 2024 (3.3%), but below the increase for 2023 (8.5%), and comes at a time of increasing scrutiny over Medicare Advantage payments.